BiomX Investor Relations Material

Latest events

KOL Event

BiomX

KOL Event

3 Apr, 2025

Q4 2024 & Study Result

31 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies

Latest reports from BiomX Inc

Access all reports
BiomX Inc. is a clinical-stage biotechnology company specializing in the development of both natural and engineered phage therapies. These therapies are designed to target and eliminate specific harmful bacteria, particularly those involved in chronic diseases. The company's key focus areas include conditions like cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX utilizes its proprietary phage technology to discover and validate bacterial targets, subsequently customizing phage compositions to combat these targets effectively. The company is headquartered in Ness Ziona, Israel, and its shares are listed on the NYSE.